Ununstandardized treatment of electroencephalographic status epilepticus does not improve outcome of comatose patients after cardiac arrest

Jeannette Hofmeijer1,2*, Marleen C. Tjepkema-Cloostermans1,3, Michiel J. Blans4, Albertus Beishuizen5 and Michel J. A. M. van Putten1,3

1 Clinical Neurophysiology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, Netherlands
2 Department of Neurology, Rijnstate Hospital, Arnhem, Netherlands
3 Department of Clinical Neurophysiology, Medisch Spectrum Twente, Enschede, Netherlands
4 Department of Intensive Care, Rijnstate Hospital, Arnhem, Netherlands
5 Department of Intensive Care, Medisch Spectrum Twente, Enschede, Netherlands

Edited by:
Edward Manno, Cleveland Clinic, USA

Reviewed by:
Laurie F. McWilliams, Cleveland Clinic, USA
Jennifer Elaine Fugate, Mayo Clinic, USA

*Correspondence:
Jeannette Hofmeijer, Department of Neurology, Rijnstate Hospital, Wagnerlaan 55, Arnhem 6815 AD, Netherlands
e-mail: jhofmeijer@rijnstate.nl

Objective: Electroencephalographic status epilepticus occurs in 9–35% of comatose patients after cardiac arrest. Mortality is 90–100%. It is unclear whether (some) seizure patterns represent a condition in which anti-epileptic treatment may improve outcome, or severe ischemic damage, in which treatment is futile. We explored current treatment practice and its effect on patients’ outcome.

Methods: We retrospectively identified patients that were treated with anti-epileptic drugs from our prospective cohort study on the value of continuous electroencephalography (EEG) in comatose patients after cardiac arrest. Outcome at 6 months was dichotomized between “good” [cerebral performance category (CPC) 1 or 2] and “poor” (CPC 3, 4, or 5). EEG analyses were done at 24 h after cardiac arrest and during anti-epileptic treatment. Unequivocal seizures and generalized periodic discharges during more than 30 min were classified as status epilepticus.

Results: Thirty-one (22%) out of 139 patients were treated with anti-epileptic drugs (phenytoin, levetiracetam, valproate, clonazepam, propofol, midazolam), of whom 24 had status epilepticus. Dosages were moderate, barbiturates were not used, medication induced burst-suppression not achieved, and treatment improved electroencephalographic status epilepticus patterns temporarily (<6 h). Twenty-three patients treated for status epilepticus (96%) died. In patients with status epilepticus at 24 h, there was no difference in outcome between those treated with and without anti-epileptic drugs.

Conclusion: In comatose patients after cardiac arrest complicated by electroencephalographic status epilepticus, current practice includes unstandardized, moderate treatment with anti-epileptic drugs. Although widely used, this does probably not improve patients’ outcome. A randomized controlled trial to estimate the effect of standardized, aggressive treatment, directed at complete suppression of epileptiform activity during at least 24 h, is needed and in preparation.

Keywords: continuous EEG, cardiac arrest, post-anoxic coma, status epilepticus, epileptic seizures, anti-epileptic drugs, prognosis

INTRODUCTION

Of comatose patients after cardiac arrest, admitted on the intensive care unit, 40–66% never regains consciousness as a result of diffuse post-anoxic encephalopathy (1–3). In these patients, a broad spectrum of electroencephalography (EEG) changes can be observed (4). Electroencephalographic seizures or status epilepticus is described in 9–35% (4–7) and is associated with poor outcome; case fatality was 90–100% in prospective case series, despite treatment with anti-epileptic drugs (2, 6, 8–13).

The diagnosis of seizures and status epilepticus on the EEG of comatose patients after cardiac arrest is controversial (14, 15). It may consist of unequivocal seizures: generalized spike–wave discharges at 3/s or faster or clearly evolving discharges of any type at 4/s or faster, either generalized or focal. However, some experts also consider other rhythmic or periodic patterns, such as generalized or lateralized periodic discharges or rhythmic delta activity, as seizure activity (16).

It is unclear whether (some) electroencephalographic seizure patterns in patients with post-anoxic encephalopathy represent
a condition, which can be treated with anti-epileptic drugs to improve patients’ outcome, or rather reflect severe ischemic damage, in which treatment is futile (17). Case series have suggested that in patients with electroencephalographic status epilepticus, preserved brainstem reactions and EEG reactivity are associated with a favorable outcome (6). However, it is unclear whether treatment with anti-epileptic drugs reduces the risk of a poor outcome in these patients. In the only prospective non-randomized intervention study, aggressive treatment up to pentobarbital induced burst-suppression resulted in a favorable outcome of 6% of patients with clinically overt or electroencephalographic status epilepticus (unpublished data). This proportion is approximately the same as reported in observational studies, irrespective of treatment (6, 10–13). Despite this lack of evidence, most neurologists treat electroencephalographic seizures and status epilepticus in comatose patients after cardiac arrest with anti-epileptic drugs. Increased detection with continuous EEG monitoring has led to increased prescription (18, 19). However, only one-third treats these patients equally aggressive to those with clinically overt status epilepticus (18, 20).

We evaluated current treatment practice, including its effects on the EEG and patients’ outcome, of seizures and electroencephalographic status epilepticus on continuous EEG in comatose patients after cardiac arrest. We used data from our prospective cohort study on the prognostic value of continuous EEG monitoring on the intensive care unit.

MATERIALS AND METHODS

PATIENTS

We retrospectively identified patients who were treated with anti-epileptic drugs (phenytoin, levetiracetam, valproate, clonazepam, or barbiturates) for electroencephalographic seizures or status epilepticus from our prospectively collected cohort of comatose patients after cardiac arrest, treated with mild therapeutic hypothermia, between June 1, 2010 and March 31, 2013. These patients were included in a prospective cohort study on the prognostic value of continuous EEG monitoring on outcome in two teaching hospitals in the Netherlands. Design, eligibility criteria, and main outcomes of the first 60 patients that were included in this study have been published previously (4). In brief, since June 1, 2010, consecutive adult comatose patients after cardiac arrest, treated with mild therapeutic hypothermia, were included within 12 h after the arrest to undergo continuous EEG monitoring on the intensive care unit. Monitoring continued until patients regained consciousness, died, or up to 5 days. The institutional review board (Medisch Ethische Toetsingscommissie Twente) waived the need for informed consent for EEG monitoring and follow-up by telephone.

TREATMENT

Comatose patients after cardiac arrest were treated according to current standard therapy, as described previously (4). In short, mild therapeutic hypothermia was induced as soon as possible after the arrest and maintained for 24 h by intravenously administered cold saline and cooling pads. Propofol, midazolam, or a combination of these was used for sedation to a level of −4 or −5 at the Richmond Agitation Sedation Scale and discontinued after normothermia had been reached, if possible. Fentanyl, remifentanil, morphine, or a non-depolarizing muscle relaxant was used against shivering.

Treatment of epileptiform discharges was not included in the study protocol. In both hospitals, decisions with regard to treatment of electroencephalographic epileptic phenomena were made by the treating intensive care physician in consultation with a neurologist/clinical neurophysiologist. Although both hospitals adhere to national guidelines for the treatment of epileptic status in general, there are no guidelines with respect to these EEG phenomena in patients with post-anoxic encephalopathy on the ICU. This indicates that both the decision to start anti-epileptic treatment, and the choice of the drugs, and the intensity of treatment were decided by the treating physician. Propofol or midazolam was identified as anti-epileptic treatment, if dosages were increased simultaneously with the initiation of treatment with anti-epileptic drugs.

EEG RECORDINGS

For all recordings, electrodes were applied according to the international 10/20 system, using 19 channels. Electrode impedances were kept below 5 kΩ. Sampling frequency was set to 256 Hz. A Neurocenter EEG system (Clinical Science Systems, Netherlands) or a Nihon Kohden system (VCM Medical, Netherlands) was used. Data were stored to disk for off-line analysis.

OUTCOME ASSESSMENT

Outcome assessment was done at 3 and 6 months after cardiac arrest by telephone by a single investigator (Marleen C. Tjepkema-Cloostermans), who was blinded for treatment with anti-epileptic drugs. The primary outcome measure of the study was the best score on the cerebral performance category (CPC) within 6 months, dichotomized between “good” (CPC 1 or 2) and “poor” (CPC 3, 4, or 5). Secondary outcome measures included mortality.

EEG ANALYSIS

Patients underwent continuous EEG monitoring, starting within 12 h after cardiac arrest, continuing until they regained consciousness, died, or up to 5 days. Real time EEG analysis was done intermittently by the consulting neurologist at the bedside, two to three times a day. Treating physicians decided on treatment with anti-epileptic drugs based on this bedside EEG analysis. However, at that time, the EEG was not used for decisions with regard to discontinuation of intensive care treatment.

Standardized, post hoc, off-line EEG analyses were performed at 24 h after cardiac arrest in automatically selected 5 min epochs. Additionally, off-line EEG analyses were done at the initiation of treatment with each anti-epileptic drug, with access to the full EEG recordings. Epochs at 24 h after cardiac arrest were analyzed independently by two investigators (Marleen C. Tjepkema-Cloostermans, Michel J. A. M. van Putten). Selection of the 5 min epochs was done by the computer and only based on absence of artifacts. Each epoch was categorized as iso-electric, low voltage, burst-suppression, diffuse slowing, normal, or epileptiform discharges. Epileptiform discharges included unequivocal, evolving seizures, and generalized periodic discharges (GPDs). The investigators were blinded for the patient’s clinical condition during the
registration, the recording time of the epoch, and the patient’s outcome. In case of disagreement, the final classification was decided by consensus. All EEGs of patients who had been treated with anti-epileptic drugs were subsequently reviewed to classify the EEG pattern at the initiation of the treatment with each additional anti-epileptic drug and to assess its effects on EEG patterns. This was done by two observers (Jeannette Hofmeijer, Michel J. A. M. van Putten), who had access to the complete recordings, but were blinded for the patients’ outcome. Electroencephalographic status epilepticus was defined as unequivocal seizures (generalized spike–wave discharges at 3/s or faster or clearly evolving discharges of any type at 4/s or faster) or other rhythmic or periodic patterns, such as generalized or lateralized periodic discharges or rhythmic delta activity, during more than 30 min. Improvement of the EEG pattern was defined as disappearance of epileptiform discharges for at least 30 min after the start of any anti-epileptic treatment. Improvement of background pattern was not taken into account.

STATISTICAL ANALYSIS
The number of patients treated with the various anti-epileptic drugs, the proportion of patients in whom treatment improved EEG patterns, and the proportion of patients with a poor outcome after treatment are presented in a descriptive way for subgroups according to EEG patterns at the time of treatment initiation. Patients treated with and without anti-epileptic drugs are compared with regard to poor outcome. These comparisons are done for subgroups according to the EEG patterns observed at 24 h after cardiac arrest. Data are presented as proportions and odds ratios, including corresponding 95% confidence intervals. Comparison of baseline characteristics was done by Student’s t-test, Chi-square test, or Fisher’s exact test, where appropriate.

RESULTS
As of March 31, 2013, 139 patients had been included (108 in Medisch Spectrum Twente and 31 in Rijnstate Hospital, Figure 1). Baseline characteristics are presented in Table 1. Blinded EEG evaluation at 24 h could be performed in 121 patients. Analysis at 24 h was not possible in 18 patients due to artifacts in the automatically selected 5 min epochs.

Thirty-one patients (22%) were treated with anti-epileptic drugs. This treatment was initiated at a median of 47 h after cardiac arrest (interquartile range 36–76). Drugs and dosages were phenytoin initial dosage 1000–1500 mg followed by 200–300 mg daily in two doses, levetiracetam 1000–1500 mg daily in two doses, valproate initial dosage 1000–1500 mg daily in two doses, clonazepam single or repeated bolus of 1 mg, Propofol 200–400 mg/h, or Midazolam 8–10 mg/h. Two patients were treated with 1, 9 with 2, 13 with 3, 5 with 4, 1 with 5, and 1 with 6 different anti-epileptic drugs. If additional anti-epileptic drugs were added, previously given medication had not sufficiently improved epileptic EEG patterns. Treatment with conventional anti-epileptic drugs continued after discharge from the ICU in surviving patients. Barbiturates were not used.

Twenty-four of the treated patients fulfilled criteria for electroencephalographic status epilepticus: 3 had evolving seizures, 12 GPDs, and 9 burst-suppression with bursts resembling epileptiform discharges during more than 30 min. Electroencephalographic status epilepticus, including evolving seizures, GPDs, and burst-suppression, started at a median of 28 h after cardiac arrest.

**FIGURE 1** | Flowchart of included patients. GPDs indicate generalized periodic discharges. Burst-suppression patterns consisted of bursts resembling epileptiform discharges of 1 up to 5 s.
Seven of the treated patients had paroxysmal epileptiform activity, but not electroencephalographic status epilepticus: five had short (3–10 s) episodes of rhythmic delta activity, and three had isolated sharp waves, both superimposed on diffusely slowed, continuous patterns. These patients all had a good outcome: three had a CPC score of 1 and 4 of 2 at 6 months (Table 2).

Patients treated with and without anti-epileptic drugs are compared with regard to the risk of poor outcome (Table 3). There were no statistically significant differences in the subgroup with status epilepticus at 24 h (evolving seizures or GPDs). Otherwise, in patients with diffusely slowed or normal EEG patterns at 24 h after cardiac arrest, the proportion of patients with a poor outcome was lower after treatment with anti-epileptic drugs.

### DISCUSSION

Retrospective analysis of treatment with anti-epileptic drugs in our prospectively collected cohort of comatose patients after cardiac arrest demonstrates that unstandardized, moderate treatment with conventional anti-epileptic drugs, not leading to complete suppression of epileptiform patterns for longer than 6 h, is common practice. There was no evidence for a beneficial effect of such treatment on outcome of patients with electroencephalographic status epilepticus.

Many of our patients who were treated with anti-epileptic drugs fulfilled the criteria for status epilepticus by semiology, EEG appearance, and duration. Still, all were treated only moderately intensive. In our cohort, moderate treatment indicated that most patients received solely conventional anti-epileptic drugs in standard doses. If propofol or midazolam was used, dosages were never sufficient to suppress epileptiform activity for more than 6 h. Barbiturates were not used and medication induced burst-suppression was never achieved. A more aggressive treatment of status epilepticus improves outcome if directed at complete suppression of electroencephalographic epileptiform discharges during at least 24 h (21). Whether this holds for status epilepticus in post-anoxic encephalopathy after cardiac arrest is unknown. Nevertheless, the moderate character of treatment in our cohort seems to be common practice and representative for the worldwide ambivalence toward treatment of electroencephalographic status epilepticus in this patient group (18, 20). This moderation reflects the uncertainty with regard to the use of any treatment.

Apart from the intensity of treatment, the onset of treatment probably plays an important role. With continuous EEG monitoring starting 12 h after cardiac arrest, we and others found that in approximately one-quarter of patients with electroencephalographic status epilepticus, the epileptiform patterns started before 24 h after cardiac arrest (4, 5, 22). In previous studies, EEG monitoring only started at a median of 2–3 days after cardiac arrest, indicating that diagnosis and subsequent treatment of electroencephalographic status epilepticus started thereafter at its earliest (6, 10, 12). In our current study, the median time to onset of electroencephalographic status epilepticus was 28 h, whereas the median time to treatment was 47 h. Mechanisms such as excessive glutamate release are known to worsen brain damage in ongoing status epilepticus within 20–40 min (23). Also, prolonged duration of status epilepticus reduces the effect of treatment, e.g., due to receptor trafficking (24). Thus, the initiation of treatment many

### Table 1 | Baseline characteristics of patients treated with and without anti-epileptic drugs.

|                          | Treatment with anti-epileptic drugs | P-value |
|--------------------------|-------------------------------------|---------|
|                          | Yes (n = 31)                        | No (n = 108) |
| Age (mean years ± SD)    | 64 ± 11                             | 65 ± 12  | 0.6  |
| OHCA                     | 29                                  | 95      | 0.4  |
| Presumed cause of cardiac arrest |                                      |         | 0.7  |
| Cardiac                  | 20                                  | 82      |       |
| Other                    | 5                                   | 11      |       |
| Unknown                  | 6                                   | 15      |       |
| Initial rhythm           |                                     |         | 0.7  |
| VF                       | 21                                  | 76      |       |
| Asystole                 | 6                                   | 17      |       |
| Bradycardia              | 2                                   | 4       |       |
| Unknown                  | 2                                   | 11      |       |
| Propofol treatment       | 28                                  | 101     | 0.7  |
| Propofol dosage (mg/kg/h, mean ± SD) | 3.0 ± 0.7                           | 2.8 ± 1.1 |       |
| Midazolam treatment      | 9                                   | 36      | 0.9  |
| Midazolam dosage (µg/kg/h, mean ± SD) | 211 ± 271                           | 309 ± 252 |       |
| Fentanyl treatment       | 17                                  | 53      | 0.4  |
| Fentanyl dosage (µg/kg/h, mean ± SD) | 1.6 ± 0.7                           | 1.8 ± 0.8 |       |
| Remifentanil treatment   | 9                                   | 33      | 0.8  |
| Remifentanil dosage (µg/kg/h, mean ± SD) | 4.7 ± 2.3                           | 4.2 ± 0.7 |       |
| Morphine treatment       | 3                                   | 23      | 0.4  |
| Morphine dosage (µg/kg/h, mean ± SD) | 331 ± 148                           | 309 ± 119 |       |

SD indicates standard deviation; OHCA, out of hospital cardiac arrest; VF, ventricular fibrillation; dosage, maximum dosage within the first 24 h.

(interquartile range 23–37). Examples are shown in Figures 2 and 3. All 24 identified patients with a status epilepticus were treated with additional anesthetics: 23 with propofol, 1 with midazolam, and 11 with a combination of propofol and midazolam. In these patients, treatment improved the EEG patterns up to temporarily physiological activity. This patient was treated with valproate, 1000 mg/day, and propofol, 2.8 mg/kg/h (Figure 4).
FIGURE 2 | Examples of EEGs of two comatose patients after cardiac arrest showing generalized periodic discharges. These patients were normothermic and sedated with propofol 1–2.5 mg/kg/h. The EEG epochs were recorded 46 h (A) or 68 h (B) after cardiac arrest. Filter settings, 0.5–30 Hz. These patients had a poor outcome.
FIGURE 3 | Examples of EEGs of two comatose patients after cardiac arrest showing evolving seizures. These patients were sedated with propofol 1–2.5 mg/kg/h. The EEG epochs were recorded 19 h after cardiac arrest, during therapeutic hypothermia (33°C) (A), or 78 h after cardiac arrest, after restoration of normothermia (B). Filter settings, 0.5–30 Hz. These patients had a poor outcome.

hours after the onset of electroencephalographic status epilepticus may be too late to prevent irreversible damage.

Previous studies have focused on electroencephalographic status epilepticus as a predictor of poor outcome after cardiac arrest and the identification of patients in whom treatment of status epilepticus might be beneficial. These have shown that sporadic patients with post-anoxic encephalopathy after cardiac arrest and electroencephalographic status
epilepticus may survive (4, 12, 13, 25). Identified possible determinants of a favorable outcome include a continuous background pattern (25), preserved brainstem reactions, and EEG reactivity (6). However, even in survivors, it remained unclear whether or not (aggressive) treatment had improved outcome, since electroencephalographic status

Table 2 | Proportions of patients with improved EEG or poor outcome after treatment with (combinations of) anti-epileptic drugs, according to the EEG pattern at the initiation of treatment.

| EEG pattern at initiation of treatment (n) | Improved EEG | Poor outcome |
|------------------------------------------|--------------|--------------|
| Evolving seizures (3) (3)                | 3 (100)      | 3 (100)      |
| GPD (12)                                 | 9 (75)       | 11 (92)      |
| Burst-suppressiona (9)                   | 3 (33)       | 9 (100)      |
| Isolated sharp waves (2)                 | 2 (100)      | 0            |
| Intermittent rhythmic delta (5)          | 5 (100)      | 0            |

Two patients were treated with 1, 9 with 2, 13 with 3, 5 with 4, 1 with 5, and 1 with 6 different anti-epileptic drugs.

aBurst-suppression patterns consisted of bursts resembling epileptiform discharges of 1 up to 5 s. Complete suppression of epileptiform patterns never lasted longer than 6 h; EEG, electroencephalography; n.a., not accessible.

In the only patient with GPDs and a good outcome, GPDs were intermixed with apparently physiological activity.

Table 3 | Proportions of patients with poor outcome treated with or without anti-epileptic drugs according to EEG pattern at 24 h after cardiac arrest.

| EEG pattern at 24 h | Poor outcome with AED n/N (%) | Poor outcome without AED n/N (%) | OR (95% CI) |
|---------------------|-------------------------------|-------------------------------|-------------|
| Iso-electric or low voltage (n = 12) | 5/5 (100) | 7/7 (100) | n.a. |
| Evolving seizures, GPD, or burst-suppression (n = 46) | 14/17 (82) | 23/29 (79) | 1.1 (0.4–3.1) |
| Continuously slowed (n = 61) | 0/5 (0) | 7/54 (13) | 0.9 (0.8–1.0) |

AED indicates anti-epileptic drugs; OR, odds ratio of poor outcome of patients treated with as compared to patients treated without AED; 95% CI, 95% confidence interval.

FIGURE 4 | Example of an EEG fragment of a comatose patient after cardiac arrest showing generalized periodic discharges intermixed with non-rhythmic activity. This patient was sedated with propofol 2.8 mg/kg/h. The EEG epoch was recorded approximately 40 h after cardiac arrest, after restoration of normothermia. Filter settings, 0.5–30 Hz. This patient had a good outcome.
epileptic after cardiac arrest is often spontaneously transient (6).

The evidence of a possible beneficial effect of anti-epileptic drugs on outcome of patients with relatively favorable EEG patterns is weak, since groups are small and bias by indication, with selective treatment of patients with a relatively good prognosis, cannot be excluded. The only neuroprotective treatment of proven benefit so far in comatose patients after cardiac arrest is mild therapeutic hypothermia (1). A randomized controlled trial on the effect of prophylactic treatment with anti-epileptic drugs is ongoing2.

This study has limitations. First, although data on patient outcome and EEG patterns were pre-defined and collected prospectively, data on the use of anti-epileptic drugs were retrieved retrospectively, implying possible observation or selection bias. Second, since evidence of effect for treatment with anti-epileptic drugs is lacking, there was no treatment protocol. Therefore, both the nature and the intensity of treatment differed among physicians. However, treatment never reached an intensity to induce burst-suppression EEG and barbiturates were not used. Third, in patients who were not treated with anti-epileptic drugs, the presence of epileptiform EEG patterns was assessed by random checks at 24 h after cardiac arrest. This indicates that the incidence of epileptiform patterns was possibly underestimated. For this reason, comparisons between patients treated with and without anti-epileptic drugs presented in Table 3 should be interpreted with caution. Fourth, although the Glasgow Coma Scale score was measured daily, information on other clinical parameters had not been collected prospectively, and retrospective collection appeared unreliable. Therefore, the proportion of patients with clinically overt myoclonic status epilepticus was unclear. However, in patients after cardiac arrest, for both electroencephalographic seizures and clinical myoclonia it is not clear whether these represent “true” seizures, with a possibility to return to physiological activity, or an expression of severe (irreversible) damage (26). For most neurologists, the threshold to treat patients with overt myoclonia is lower than for patients with non-convulsive electroencephalographic seizures. However, irreversible damage is probably even more likely in patients with myoclonia, since the risk of poor outcome is larger (6) and neuronal necrosis is more common (26). Fifth, we selected patients based on treatment with specific anti-epileptic drugs and only identified continuously infused propofol or midazolam as a treatment against electroencephalographic seizures, if dosages increased simultaneously with the initiation of treatment with anti-epileptic drugs. We cannot exclude that in some other patients electroencephalographic seizures were treated solely with propofol or midazolam.

CONCLUSION

In comatose patients after cardiac arrest with electroencephalographic status epilepticus, unstandardized treatment with conventional anti-epileptic drugs in standard doses, that only suppresses pathological EEG patterns temporarily (<6 h), is common practice. Although widely used, such treatment does probably not improve patients’ outcome. A randomized controlled trial to estimate the effect of early and aggressive treatment, directed at complete suppression of epileptiform activity during at least 24 h, is needed and in preparation (unique identifier NCT02056236)2.

AUTHOR CONTRIBUTIONS

Jeannette Hofmeijer, Marleen C. Tjepkema-Cloostermans, Michel J. A. M. van Putten: study design and conceptualization, data interpretation and analysis, and writing or revising the manuscript. Michiel J. Blans, Albertus Beishuizen: data interpretation and analysis, and writing or revising the manuscript.

ACKNOWLEDGMENTS

Marleen C. Tjepkema-Cloostermans was financially supported by the Dutch Ministry of Economic Affairs, Agriculture and Innovation, province Overijssel and province Gelderland through the VIP Brain Networks project. All intensive care units’ and clinical neurophysiology departments’ staff and personnel of Medical Spectrum Twente and Rijnstate Hospital are kindly acknowledged for the constructive collaboration.

REFERENCES

1. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Coma after cardiac surgery without cardiac arrest: a prospective cohort study. N Engl J Med (2002) 346:557–63. doi:10.1056/NEJMoa023829
2. Krumholz A, Stern BJ, Weiss HD. Outcome from coma after cardiopulmonary resuscitation: relation to seizures and myoclonus. Neurology (1988) 38:401–5. doi:10.1212/0052238.401
3. Zandbergen EG, Hijdra A, Koelman JH, Hart AA, Vos PE, Verbeek MM, et al. Predictors of poor outcome after therapeutic hypothermia: a pilot study. Neurocrit Care (2012) 16:744–9. doi:10.1007/s12028-011-9565-0
4. Rossetti AO, Oddo M, Liaudet L, Kaplan PW. Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology (2009) 72:744–9. doi:10.1212/01.wnl.0000343006.60851.62
5. Zandbergen EG, Hijdra A, Koelman JH, Hart AA, Vos PE, Verbeek MM, et al. Prediction of poor outcome within the first 3 days of postanoxic coma. Neurology (2006) 66:62–8. doi:10.1212/01.wnl.0000191308.22333.88
6. Celles C, Grigg MM, Ross E. Generalized status myoclonicus in acute anoxic and toxic–metabolic encephalopathies. Arch Neurol (1988) 45:781–4. doi:10.1001/arch Neurol.1988.0050261.0090923
7. Hofmeijer JC, Popescu A, Brenner RP, Gayette FX, Callaway CW. Frequency and timing of nonconvulsive status epilepticus in comatose post-cardiac arrest subjects treated with hypothermia. Neurocrit Care (2012) 16:114–22. doi:10.1007/s12028-012-9565-0
8. Rossetti AO, Oddo M, Liaudet L, Kaplan PW. Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology (2009) 72:744–9. doi:10.1212/01.wnl.0000343006.60851.62
9. Zandbergen EG, Hijdra A, Koelman JH, Hart AA, Vos PE, Verbeek MM, et al. Prediction of poor outcome within the first 3 days of postanoxic coma. Neurology (2006) 66:62–8. doi:10.1212/01.wnl.0000191308.22333.88
10. Celles C, Grigg MM, Ross E. Generalized status myoclonicus in acute anoxic and toxic–metabolic encephalopathies. Arch Neurol (1988) 45:781–4. doi:10.1001/arch Neurol.1988.0050261.0090923
11. Hui AC, Cheng C, Lam A, Mok V, Joynt GM. Prognosis following postanoxic anoxic and toxic-metabolic encephalopathies. Arch Neurol (2008) 65:2867–75. doi:10.1007/CCM.0b013e31825b0480
12. Rittenberger JC, Popescu A, Brenner RP, Gayette FX, Callaway CW. Frequency and timing of nonconvulsive status epilepticus in comatose post-cardiac arrest subjects treated with hypothermia. Neurocrit Care (2012) 16:114–22. doi:10.1007/s12028-011-9565-0
13. Rossetti AO, Oddo M, Liaudet L, Kaplan PW. Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology (2009) 72:744–9. doi:10.1212/01.wnl.0000343006.60851.62
14. Zandbergen EG, Hijdra A, Koelman JH, Hart AA, Vos PE, Verbeek MM, et al. Prediction of poor outcome within the first 3 days of postanoxic coma. Neurology (2006) 66:62–8. doi:10.1212/01.wnl.0000191308.22333.88
15. Celles C, Grigg MM, Ross E. Generalized status myoclonicus in acute anoxic and toxic–metabolic encephalopathies. Arch Neurol (1988) 45:781–4. doi:10.1001/arch Neurol.1988.0050261.0090923
16. Hui AC, Cheng C, Lam A, Mok V, Joynt GM. Prognosis following postanoxic myoclonus status epilepticus. Eur Neurol (2005) 46(3):10–3. doi:10.1159/000086755
17. Kaplan PW, Morales Y. Status epilepticus: an independent outcome predictor after cerebral anoxia. Neurology (2008) 70:1295–6. doi:10.1212/01.wnl.0000320747.77793.4d
18. Legriel S, Bruneel F, Sediri H, Hilly J, Abbosh N, Lagarrigue MH, et al. Early EEG monitoring for detecting postanoxic status epilepticus during therapeutic hypothermia: a pilot study. Neurocrit Care (2009) 11:338–44. doi:10.1007/s10572-009-9246-4
19. Rossetti AO, Logroscino G, Liaudet L, Rufieux C, Ribordy V, Schaller MD, et al. Status epilepticus: an independent outcome predictor after cerebral anoxia. Neurology (2007) 69:255–60. doi:10.1212/01.wnl.0000265819.36639.e0

1http://clinicaltrials.gov/ct2/show/NCT01083784
2http://www.clinicaltrials.gov
13. San-Juan OD, Chiappa KH, Costello DJ, Cole AJ. Periodic epileptiform discharges in hypoxic encephalopathy: BiPLEDs and GPEDs as a poor prognosis for survival. Seizure (2009) 18:365–8. doi:10.1016/j.seizure.2009.01.003

14. Brenner RP. Is it status? Epilepsia (2002) 43(Suppl 3):103–13. doi:10.1046/j.1528-1157.43.s.3.x

15. Chong DJ, Hirsch LJ. Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol (2005) 22:79–91. doi:10.1097/01.WNP.0000158699.78529.AF

16. Hirsch LJ. Atlas of EEG in Critical Care, Wiley Blackwell (2010). doi:10.1002/9780470746707

17. Tjepkema-Cloostermans MC, Hindriks R, Hofmeijer J, van Putten M. Generalized periodic discharges after acute cerebral ischemia: reflection of selective synaptic failure? Clin Neurophysiol (2014) 125(2):255–62. doi:10.1016/j.clinph.2013.08.005

18. Abend NS, Dlugos DJ, Hahn CD, Hirsch LJ, Herman ST. Use of EEG monitoring and management of non-convulsive seizures in critically ill patients: a survey of neurologists. Neurocrit Care (2010) 12:382–9. doi:10.1007/s12028-010-9337-2

19. Kilbride RD, Costello DJ, Chiappa KH. How seizure detection by continuous electroencephalographic monitoring affects the prescribing of antiepileptic medications. Arch Neurol (2009) 66:723–8. doi:10.1001/archneurol.2009.100

20. Bouwes A, Kuiper MA, Hijdra A, Horn J. Induced hypothermia and determination of neurological outcome after CPR in ICUs in the Netherlands: results of a survey. Resuscitation (2010) 81:393–7. doi:10.1016/j.resuscitation.2009.12.032

21. Shorvon S. Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation. Epilepsia (2011) 52(Suppl 8):33–6. doi:10.1111/j.1528-1167.2011.02328.x

22. Mani R, Schmitt SE, Mazer M, Putt ME, Gaieski DF. The frequency and timing of epileptiform activity on continuous electroencephalogram in comatose post cardiac arrest syndrome patients treated with therapeutic hypothermia. Resuscitation (2012) 83:840–7. doi:10.1016/j.resuscitation.2012.02.015

23. Fujikawa DG. Prolonged seizures and cellular injury: understanding the connection. Epilepsy Behav (2005) 7(Suppl 3):S3–11. doi:10.1016/j.yebeh.2005.08.003

24. Naylor DE, Liu H, Wusterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci (2005) 25:7724–33. doi:10.1523/JNEUROSCI.4944-04.2005

25. Rundgren M, Westhall E, Cronberg T, Rosen I, Friberg H. Continuous amplitude-integrated electroencephalogram predicts outcome in hypothermia-treated cardiac arrest patients. Crit Care Med (2010) 38:1838–44. doi:10.1097/CCM.0b013e3181ea1c7

26. Young GB, Gilbert JJ, Zochodne DW. The significance of myoclonic status epilepticus in postanoxic coma. Neurology (1990) 40:1843–8. doi:10.1212/WNL.40.12.1843

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 14 January 2014; accepted: 17 March 2014; published online: 31 March 2014. Citation: Hofmeijer J, Tjepkema-Cloostermans MC, Hindriks R, Hofmeijer J, van Putten M. Unstandardized treatment of electroencephalographic status epilepticus does not improve outcome of comatose patients after cardiac arrest. Front. Neurol. 5:39. doi: 10.3389/fneur.2014.00039

This article was submitted to Neurocritical and Neurohospitalist Care, a section of the journal Frontiers in Neurology.

Copyright © 2014 Hofmeijer, Tjepkema-Cloostermans, Hindriks, Beishuizen and van Putten. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.